Significance of intraoperative testing in right-sided implantable cardioverter-defibrillators

Andreas Keyser1*, Michael K Hilker1, Ekrem Ücer2, Sigrid Wittmann3, Christof Schmid1 and Claudius Diez1

Abstract

Background: Implantation of implantable cardioverter-defibrillators (ICD) from the left pectoral region is the standard therapeutic method. Increasing numbers of system revisions due to lead dysfunction and infections will consecutively increase the numbers of right-sided implantations. The reliability of devices implanted on the right pectoral side remains controversially discussed, and the question of testing these devices remains unanswered.

Methods: In a prospectively designed study all 870 patients (60.0±14 years, 689 male) who were treated with a first ICD from July 2005 until May 2012 and tested intraoperatively according to the testing protocol were analyzed. The indication for implantation was primary prophylactic in 71.5%. Underlying diseases included ischemic cardiomyopathy (50%), dilative cardiomyopathy (37%), and others (13%). Mean ejection faction was 27±12%.

Results: Five patients supplied with right-sided ICD (13%, p = 0.02 as compared to left-sided) failed initial intraoperative testing with 21 J. 3 patients were male. The age of the patients failing intraoperative testing with right-sided devices appeared higher than of patients with left-sided devices (p = 0.07). The ejection fraction was 28±8%. All patients reached a sufficient DFT ≤ 21 J after corrective procedures.

Conclusion: Implantation of ICDs on the right side results in significantly higher failure rate of successful termination of intraoperatively induced ventricular fibrillation. The data of our study suggest the necessity of intraoperative ICD testing in right-sided implanted ICDs.

Keywords: Implantable cardioverter defibrillator, Right-sided implantation, Intraoperative test
was obtained from each patient and approval of the institutional review board is given. Within the study period from July 2005 until May 2012, 876 patients received their first ICD (1-, 2-, and 3-chamber) devices.

Exclusion criteria

Left ventricular thrombi were regarded as exclusion criterion to reduce the risk of embolization with respect to the intraoperative testing procedure. Patients requiring epicardial defibrillator patches also were excluded as they were not treated with endocardial defibrillator leads.

The primary endpoint of the study was patients failing the initial intraoperative testing of the system implanted.

Surgery

All patients underwent general anesthesia for the operative procedure which was performed by a cardiac surgeon. Leads were placed via a cephalic vein and/or subclavian vein. Only dual coil defibrillation leads were implanted. Left ventricular leads were positioned either endocardially or epicardially. All devices were implanted subpectorally.

The devices were implanted on the left side in 831 (95.5%) of the patients. Due to occluded left subclavian vein or pacemaker on the right side 39 patients were treated with right sided devices.

All implanted systems were high energy ICDs with maximum deliverable shock energy ≥31 Joule (J) (Biotronic, Boston Scientific, Medtronic, and St. Jude Medical). Ventricular leads were placed in a right apical position, the distal end of the proximal coil near the atrium/superior caval vein junction. An adequate ventricular sensing of >6 mV and a pacing threshold of <1 V was attempted in all cases. Any antiarrhythmic therapy was recorded.

Testing

Initial testing was performed using active can and dual coil transvenous lead. The superior caval vein coil and right ventricular coil was the cathode for the biphasic shock. According to the testing protocol ventricular fibrillation (VF) was induced by T-wave shock or - if T-wave shock failed to induce VF - by 50Hz pacing. The test shock was programmed at delivered energy of 21 J. The delivered energy of 21 J corresponds to a 10 J safety margin of a 31 J device. To avoid bias in the study, the 21 J margin was chosen, even if the delivered energy of an implanted device might have exceeded 31 J. In case of ongoing VF external defibrillation followed to terminate VF. If successful termination of VF could not be achieved with internal electrodes, the defibrillation lead was repositioned and testing was repeated, again with 21 J. Programming reversed polarity, single coil, and relocation of the device caudo-medially or laterally followed as further options if the system still failed to terminate VF, each step being tested again with 21 J.

Statistical analysis

Statistical analysis was performed with Stata 10.1 SE for Windows (StataCorp, College Station, TX, USA). Continuous data were first tested for normality with the Shapiro-Wilk test and graphically with Quantile-Quantile plots. If normally distributed, these data are presented as mean (± standard deviation) or, if non-normally distributed, as median with interquartile range. Dichotomous data were expressed as numbers and percentages. Univariate comparisons were tested with Fisher’s exact test or the Chi-square test for categorical variables. The t test was used for continuous normally-distributed variables or Mann-Whitney’s test for non-normally distributed data. The tests were performed two sided and a p-value of <0.05 was considered statistically significant.

Results

Due to left cavity thrombi four patients had to be excluded from the study. Another two patients requiring epicardial defibrillator patches also had to be excluded. In the investigated group of 870 patients operated within the last six years no major adverse events including death, stroke, and cardio-pulmonary depression occurred during implantation and testing. 39 patients had right pectoral implantation of their device (4.5%).

Overall, 38 (4.3%) patients had a DFT >21 J with the initial shock configuration and underwent system correction. The mean age of patients failing the initial test with left sided devices proved to be significant lower when compared to the age of the general study population (60±14 years versus 51±14 years - ranging from 22 to 71 years, p<0.0001). Mean age of the patients with right-sided devices and failing the initial intraoperative test was comparable to the study population, and higher when compared to left-sided devices failing the initial intraoperative test (left 49.6±14 years, right 61.5±7 years, p=0.07). There were 25 male and 13 female patients. The ejection fraction was comparable in both groups. The initial test was failed by a total of 38 ICDs, 33 were implanted on the left (87%) and 5 on the right side (13%). The failing rate of implanted devices on the right side appeared to be significant lower when compared to the age of the general study population (60±14 years versus 51±14 years - ranging from 22 to 71 years, p<0.05). The ejection fraction was comparable in both groups.

Of the 39 devices implanted right pectorally the indication for ICD implantation was prophylactic in 28 cases according to the MADIT criteria [9]. The underlying diagnosis of non-ischemic dilated cardiomyopathy was found in 16 of the 39 patients, the remaining 23 patients suffered from ischemic cardiomyopathy. Underlying diseases of the patients and indication for device implantation are summarized in Table 2.

We supplied 16 patients with a VVI system; three of them presented with chronic atrial fibrillation. A DDD-system was provided in 16 patients: 6 of them suffered
Discussion

As the implantation of ICDs from the left pectoral region is accepted standard procedure, right sided implantations remain an exception [2-8]. A glimpse into the future unveils an increasing number of system revisions due to lead dysfunction and infections [10]. Consecutively the number of ICDs implanted in the right pectoral region will increase, and the question of intraoperative testing in right-sided devices will gain a new and more important quality.

Significant higher thresholds of right pectorally implanted ICDs as compared to left-sided implantations have been reported, and most of the literature was published prior to the introduction of high energy devices with a new generation of capacitors with quick energy supply [2-8]. A failing of intraoperative testing has so far explicitly only been discussed in a case report [11].

Only the determination of the DFT or a safety margin of 10 J tested intraoperatively indicates appropriate function of the implanted system. Furthermore, the detection of ventricular arrhythmias (VAs, e.g. ventricular tachycardia and/or fibrillation), lead function, and system integrity are checked while testing, latter to detect the rare case of device failure [12]. The aim of a safety margin of 10 J – as in our study – lowers the probability of retesting. In addition, testing a 10 J safety margin tends to have enough evidence and is generally accepted [13].

In our study, designed to include all consecutive patients (all comers), we found a failing first shock rate of 13% in patients having their device implanted right pectorally. An inadequate safety margin of less than 10 J is found in 6.2% up to 17% of patients receiving an ICD (left sided) [14,15]. In left pectorally implanted ICDs, lead repositioning, device relocation, additional leads, and changing device polarity are recommended to avoid insufficient therapy, e.g. failing of necessary cardioversion and/or defibrillation, if the intraoperative test fails [16-18].

In the study of Kirk [7] one fourth (25) of the patients received right-sided implants of ICDs. The study population is rather small. Only one patient failed adequate intraoperative DFT-testing. Neither Gold [8] nor we experienced such a high amount of patients presenting contraindications for left-sided implants. As the populations obviously differ concerning indication to right-sided implantation they seem not to be comparable.

Gold [8] used a DFT-protocol not being completed in three patients (7.3%) with right-sided implants because of high thresholds. Yet Gold does not describe alterations of the implants to achieve appropriate intraoperative testing results. And he found a near doubling of the mortality rate among patients with right-sided implants in his follow up. The question arouses whether there might be a link between testing failure and mortality in the study of Gold. We tested a safety margin, having found an initial failing of the intraoperative test in 5 patients. All these five patients achieved an appropriate safety margin of ≤21 J by altering the ICD system implanted (see Table 4).

An adequate ventricular sensing of >6 mV (10.8±0.3 mV) and a pacing threshold of <1 V (0.6±0.2 V/0.5 ms) was achieved in all patients, prior to testing. As all our patients achieved these values we must question whether right ventricular stimulation threshold alone has enough evidence for appropriate device function [19]. Five of our patients received amiodarone or any other antiarhythmic therapy at the time of implantation.

From sick sinus syndrome, 6 from intermittent atrial fibrillation, two patients from AV block II type Mobitz and AV block III, respectively. Seven patients were treated with cardiac resynchronization therapy (CRT-D) due to additional left bundle branch block (Table 3). Right ventricular sensing was adequate in all patients with 10.8±3 mV. The pacing threshold was 0.6±0.2 V/0.5 ms. None of the patients received amiodarone or any other antiarrhythmic therapy at the time of implantation.

All patients successfully reached a DFT ≤21 J (that is a safety margin > 10 J) by changing the position of the ICD-lead, replacing the device and/or optimizing the shock configuration (Table 4).

Table 1 Successful versus unsuccessful initial intraoperative testing

| Variable | Left sided implantation | Right sided implantation | Total |
|----------|-------------------------|--------------------------|-------|
|          | Successful [n=798] | Unsuccessful [n=33] | p-value | Successful [n=34] | Unsuccessful [n=5] | p-value |
| Age [years] | 60 ± 14 | 50 ± 14 | < 0.0001 | 63 ± 13 | 62 ± 7 | 0.77 |
| Gender | | | | | | |
| Males | 637 | 22 | 0.08 | 27 | 3 | 0.57 |
| Females | 161 | 11 | | 7 | 2 | |
| Ejection fraction [%] | 27 ± 12 | 24 ± 12 | 0.15 | 26 ± 12 | 28 ± 8 | 0.72 |

Comparisons. Age: Unsuccessful left versus Unsuccessful right: p=0.07.

Table 2 Baseline characteristics

| Variable | Left sided implantation | Right sided implantation | p-value |
|----------|-------------------------|--------------------------|---------|
|          | Successful [n=798] | Unsuccessful [n=33] |          | Successful [n=34] | Unsuccessful [n=5] |          |
| Age [years] | 60 ± 14 | 50 ± 14 | < 0.0001 | 63 ± 13 | 62 ± 7 | 0.77 |
| Gender | | | | | | |
| Males | 637 | 22 | 0.08 | 27 | 3 | 0.57 |
| Females | 161 | 11 | | 7 | 2 | |
| Ejection fraction [%] | 27 ± 12 | 24 ± 12 | 0.15 | 26 ± 12 | 28 ± 8 | 0.72 |

Comparisons. Age: Unsuccessful left versus Unsuccessful right: p=0.07.
39 patients had corrections of their implanted devices due to failing shock at the first attempt. Thus, our data will not strain the conclusion to refrain from intraoperative testing as a consequence of an adequate right ventricular threshold when implanting devices right pectorally.

Four of our 39 patients failing the initial intraoperative test had pacemaker leads implanted prior to the ICD implantation. The abandoned right ventricular lead of three of our six patients with right-sided devices might have had an impact on the testing procedure, even though Glikson has shown no increased risk of abandoned right ventricular leads in patients being supplied with left-sided ICDs [20].

Amiodarone is reported to have an impact on failing therapies in patients supplied with an ICD [14,21]. Napp therefore recommends intraoperative ICD testing in these cases [21]. As Napp especially recommends testing in young patients treated with amiodarone, and as Napp questioned the need of intraoperative testing in his title we must stress, that in absence of medication with amiodarone abstaining from testing cannot be recommended for right pectorally implanted ICDs. None of our patients failing the initial intraoperative test with right sided devices was treated with amiodarone or any other antiarrhythmic medication perioperatively.

The need of cardioversion and/or defibrillation might be necessary as well when antitachycardia pacing (ATP) as alternative therapy of VAs for these severe arrhythmias fails [22]. Even if up to 80% of VAs may be treated sufficiently with ATP, this different mode of therapy cannot justify arguing against intraoperative testing, as Viskin concludes [23].

The main arguments against intraoperative testing are major adverse events such as intractable VF, hemodynamic deterioration, neurological impairment, and death [24-26]. Death in accordance to defibrillator testing has a prevalence of 0.016% in the Canadian population of 19067 patients through 0.2% of 440 patients published by Alter.

Table 3: Indications for the implantable defibrillator (ICD) implantation

|                | Left implantation | Right implantation |
|----------------|-------------------|---------------------|
|                | DCM<sup>b</sup>  | ICM<sup>b</sup>    | Other<sup>c</sup>  | DCM | ICM | Other |
| Successful [n; %] | 289; 93%         | 404; 98%           | 105; 100%          | 13; 81% | 21; 91% | 0     |
| Failure [n; %]   | 23; 7%           | 10,2%              | 0; 0%              | 3; 19% | 2,9% | 0     |
| <p>0.0001 (FET) | p = 0,63 (FET)   |                    |                    |       |       |       |
| Primary<sup>d</sup> | Secondary<sup>e</sup> | Primary | Secondary |
| Successful [n; %] | 566; 96%         | 232; 97%           | 8; 3%              | 8; 23% | 3; 60% |       |
| Failure [n; %]   | 25; 4%           | 8; 3%              |                    | 2; 12% | 3; 19% | 0; 0% |
| p = 0,59        |                  |                    |                    |       |       |       |
| <p>Primary<sup>d</sup> | Secondary<sup>e</sup> | Primary | Secondary |
| Successful [n; %] | 496; 97%         | 204; 94%           | 98; 96%            | 14; 88% | 13; 81% | 7; 100% |
| Failure [n; %]   | 17; 3%           | 12; 6%             | 4; 4%              | 2; 12% | 3; 19% | 0; 0% |
| p = 0,34 (FET)  |                  |                    |                    |       |       |       |

FET – Fisher’s exact test.
<sup>b</sup>DCM – Nonischemic dilatative cardiomyopathy.
<sup>c</sup>ICM – Ischemic cardiomyopathy.
<sup>d</sup>Other – Hypertrophic obstructive cardiomyopathy, amyloidosis, fibrosis.
<sup>e</sup>Primary – Primary prevention indication.
<sup>f</sup>Secondary – Secondary prevention indication.
<sup>g</sup>VVI One chamber ICD.
<sup>h</sup>DDD Dual chamber ICD.
<sup>i</sup>CRT Cardiac resynchronization therapy.

Table 4: Corrective measures in patients with primary right sided implantation

| No | Age [years] | Gender | Pace/sense | Lead reposition | Dual → single lead | Reverse polarity | Device reposition | Total no of shocks<sup>a</sup> |
|----|-------------|--------|------------|-----------------|-------------------|------------------|-------------------|-------------------------------|
| 1  | 50          | Male   | 0.5 V; 0.5 ms/14 mV | 1 | 1 | 5 (2) |
| 2  | 70          | Male   | 0.7 V; 0.5 ms/11 mV | 1 | 3 (1) |
| 3  | 64          | Female | 0.4 V; 0.5 ms/16 mV | 1 | 1 | 7 (3) |
| 4  | 63          | Male   | 0.9 V; 0.5 ms/10 mV | 1 | 3 (1) |
| 5  | 61          | Female | 0.7 V; 0.5 ms/15 mV | 1 | 3 (1) |

<sup>a</sup>No of intraoperative shocks; (no of external defibrillations).
and 0.4% stated by Kolb [24,25,27]. Strokes have been observed in 0.026% in the Canadian study through 0.5% by Alter [24,25]. The Canadian study is being multiply cited in the use for arguments against intraoperative testing. But Healey could verify these results in his study of 2173 patients finding no differences in the perioperative complications in patients having been tested or not [28]. In our total collective of 1668 patients treated since 1996 we observed no stroke and no deaths related to intraoperative testing. An adequate surgical implantation time as well as a strict agreement in the operating theatre concerning therapeutically procedures in case of intractable VF enhances the safety of a patient.

Stickberger et al. assumed an efficacy of about 5% when additional modifications of the implanted systems are necessary to achieve an adequate DFT [29]. Our system revisions after failed initial testing, however, were uniformly successful.

Finally, Strickberger states that the elimination of DFT or safety margin testing offers the opportunity to treat more patients with ICDs [29]. But would we willingly accept a high failing rate in our patients, especially when implanting devices right-sided? Even if ICDs represent a life-saving tool in the therapy of sudden onsets of VAs physicians should not abandon the standard of care for their patients.

Conclusion

The development of new ICD-leads, shock algorithms, high energy defibrillators, and quick energy supply has improved the ICD devices. Nevertheless, the implantation of ICDs on the right side results in significantly higher failure rate of successful terminating intraoperatively induced ventricular fibrillation. Alterations of the implanted system such as lead repositioning, device relocation, and changing device polarity are effective means to achieve sufficient sensing of VAs and an appropriate safety margin to terminate life threatening VAs. The data of our study strongly suggest the necessity of intraoperative ICD testing in right-sided implanted ICDs.

Abbreviations

ATP: Antitachycardia pacing; AV block: Anti-ventricular block; CRT-D: Cardiac resynchronization therapy-defibrillator; DCM: Dilative cardiomyopathy; ICD: Implantable cardioverter defibrillator; DFT: Defibrillation threshold; DDD: Dual chamber; EF: Ejection fraction; ICM: Ischemic cardiomyopathy; J: Joule; ms: Milliseconds; mV: millivolt; V: Volt; VA: Ventricular arrhythmia; VF: Ventricular fibrillation; VVI: One chamber.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

AK is the guarantor of the manuscript. AK contributed to the study conception and design; acquisition, analysis and interpretation of data; drafting the article; and revising, reading, and approving the final version of the article. MKH contributed to conception and design and helped draft the manuscript. EU contributed substantially to the design and to the interpretation of data. SW helped draft the manuscript and contributed to the interpretation of data. CS contributed to conception and design of the study, contributed to the interpretation and helped draft the manuscript. CD helped design the study, contributed to the conception, performed the statistical analysis and helped draft the manuscript. All authors read and approved the final manuscript.

Acknowledgement

M Ried assisted in acquisition of data and read and approved the manuscript. S Festner and C Jungbauer assisted in acquisition of data. We thank all the staff of the departments involved in patient care and evaluation.

Author details

1Department of Cardiac Surgery, University Medical Center, Regensburg, Germany. 2Department of Cardiology, University Medical Center, Regensburg, Germany. 3Department of Anesthesiology, Regensburg, Germany.

Received: 12 November 2012 Accepted: 8 April 2013

Published: 11 April 2013

References

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Pole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10:2388–2442.
2. Epstein AE, Kay GN, Plumb VJ, Voshage-Stahl L, Hull M. Elevated defibrillation threshold when right-sided venous access is used for nonthoracotomy ICD lead implantation. J Cardiovasc Electrophysiol 1995, 11:579.
3. Natale A, Sja J, Geiger MJ, Newby K, Afshar M, Pacifico A: Right side implant of the unipolar single lead defibrillation system. Pace 1997, 20:1910–1912.
4. Jensen SM, Pietersen A, Chen X: Implantation of Can Implantable Defibrillators in the right pectoral region. Pace 1998, 21:476–477.
5. Roberts PR, Allen S, Betts T, Urban JF, Whitman T, Euler DE, Kalkof MJ, Morgan JM. Increased defibrillation threshold with right-sided active pectoral can. J Intervent Cardiac Electrophysiol 2000, 2245–249.
6. Fonteyne W, Rottiers H, Tavener R: Experience with right sided implantation of transvenous active can cardioverter defibrillators. Europace 2001, 2(Suppl 1):A30.
7. Kirk MM, Sharochki SR, Gold MR: Comparison of the effects of active left and right pectoral pulse generators on defibrillation efficacy. Ann J Cardiol 2001, 88:1308–1311.
8. Gold MR, Shih HT, Herre J, Breiter D, Zhang Y, Schwartz M: Comparison of defibrillation efficacy and survival associated with right versus left pectoral placement for implantable defibrillators. Am J Cardiol 2007, 100:243–246.
9. Moss AJ, Zareba WJ, Hall WI, Klein H, Wilber DJ, Cannon DS, Daubert JP, Higgins SL, Brown MM, Andrews ML: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877–883.
10. Greenspon AJ, Patel JD, Lau E, Ochoa J, Frisch DR, Ho RT, Pavri BB, Kurtz SM: 16-year tends in the infection burden of pacemakers and implantable cardioverter-defibrillators in the United States. J Am Coll Cardiol 2011, 58:1001–1006.
11. Parson K, Reddy V: Optimizing the defibrillation vector with a right-sided implantable cardioverter-defibrillator. Hear Rhythm 2004, 6:756.
12. Ikeler RE, Epstein AE, Plump VJ: Should shocks still be administered during implantable cardioverter-defibrillator insertion? Hear Rhythm 2005, 2:462–463.
13. Day JD, Doshi RN, Belott P, Biersdorfer-Green U, Bebbohddahk M, Ott P, Gatter KA, Tobias S, Frumin H, Lee BK, Merillat J, Wiener I, Wang S, Grogan H, Chun S, Patrawala R, Crandall B, Osborn JS, Weiss JP, Lappe DL, Neuman S: Inductionless or limited shock testing is possible in most patients with implantable cardioverter-defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (arrhythmia single
shock defibrillation threshold testing versus upper limit of vulnerability: risk reduction evaluation with implantable cardioverter-defibrillator implantation). Circulation 2007; 115:2382–2389.

14. Russo AM, Sauer W, Gerstenfeld EP, Hisa HH, Lin D, Cooper JM, Dzion S, Vendrusco RJ, Nayak HM, Callans DJ, Patel V, Marchlinski FE: Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm 2005; 2:456–461.

15. Blatt JA, Poole JE, Johnson GW, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Anderson J, Chung K, Wong WS, Mark DB, Lee KL, Barry Gh: SCD-HeFT Investigators. No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol 2008; 52:551–556.

16. Gold M-R, Olszewsky MR, DeGroot PJ, Cuello C, Shorofsky SR: Optimization of transvenous coil position for active can defibrillation thresholds. J Cardiovasc Electrophysiol 2000; 11:25–29.

17. Rashba EJ, Bonner M, Wilson J, Shorofsky SR, Peters RW, Gold MR: Distal right ventricular coil position reduces defibrillation thresholds. J Cardiovasc Electrophysiol 2003; 14:1036–1040.

18. Unui M, Walcott GP, Kemknights BH, Walker RG, Rollins DL, Smith WM, Ideker RE: Influence of malpositioned transvenous leads on defibrillation efficacy with and without a subcutaneous array electrode. Pacing Clin Electrophysiol 1995; 18:2008–2016.

19. Atary JZ, Borleffs CJ, van der Born JG, Trines SA, Bootma M, Zeppenfeld K, van Erven L, Schalij MJ: Right ventricular stimulation threshold at ICD implant predicts device therapy in primary prevention patients with ischaemic heart disease. Europace 2010; 12:1581–1588.

20. Glikson M, Suleiman M, Luria DM, Martin ML, Hodge DO, Shen WK, Bradley DJ, Munger TM, Rea RF, Hayes DL, Hammill SC, Friedman PA: Do abandoned leads pose risk to implantable cardioverter-defibrillator patients? Heart Rhythm 2009; 6:65–68.

21. Napp A, Birkenhauer F, Lee KM, Gemein C, Zink M, Knackstedt C, Marx N, Schauerte P, Mischke K: ICD-Test: Is the evaluation of the defibrillation threshold (DFT) still up to date? The ATLANTIS Register. Eur Heart J 2010; 31:928–929.

22. Watthen MS, DeGroot PJ, Sweeney MO, Stark AJ, Ottersen MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ: PainFREE Rx II: Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing fast ventricular tachycardia reduces shock therapies (PainFREE Rx II) trial results. Circulation 2004; 110:2591–2596.

23. Viskin S, Rosse R: The top 10 reasons to avoid defibrillation threshold testing during ICD implantation. Hear Rhythm 2008; 5:391–393.

24. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W: Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol 2005; 28:926–932.

25. Birnie D, Tung S, Simpson C, Crystal E, Exner D, Ayala Paredes FA, Kranh A, Parkash R, Khaykin Y, Philippos F, Guerra P, Kimber S, Cameron D, Healey JS: Complications associated with defibrillation threshold testing: the Canadian experience. Hear Rhythm 2008; 5:391–393.

26. Brignole M, Ractti G, Bongioni MG, De Martino G, Favale S, Gaparini M, Kolb C, Tzeis S, Zrenner B: Defibrillation testing at the time of implantation of cardiovascular defibrillation in the clinical practice: a nation-wide survey. Europace 2007; 9:540–543.

27. Kolb C, Tzeis S, Zrenner B: Defibrillation threshold testing: tradition or necessity? Pacing Clin Electrophysiol 2009; 32:570–572.

28. Healey JS, Birnie DH, Lee DS, Kranh AD, Crystal E, Simpson CS, Dotan P, Chen Z, Cameron D, Verna A, Connolly SJ, Gula LJ, Lockwood E, Nair G, Tu JV: Defibrillation testing at the time of ICD insertion: an analysis from the Ontario ICD registry. J Cardiovasc Electrophysiol 2010; 21:1344–1348.

29. Strickberger SA, Klein GJ: Is defibrillation testing required for defibrillator implantation? J Am Coll Cardiol 2004; 44:889–91.